Regeneron Pharmaceuticals, Inc. (REGN)
| Previous close | 476.36 |
| Open | 476.22 |
| Bid | 473.08 x 1000 |
| Ask | 475.69 x 1100 |
| Day's range | 471.50 - 480.26 |
| 52-week range | 441.00 - 664.64 |
| Volume | 679,574 |
| Avg. volume | 1,033,762 |
| Market cap | 50.906B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 15.57 |
| EPS (TTM) | 30.52 |
| Earnings date | 06 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 647.96 |
- Editor's pickYahoo Finance Video
Pfizer’s vaccine EUA expansion request is ‘extremely welcomed’: Doctor
Dr. Shereef Elnahal, University Hospital CEO, Former NJDOH Commissioner, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on coronavirus vaccines.
- PR Newswire
NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at High Risk of Clinical Progression
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that newly updated National Institutes of Health (NIH) COVID-19 Treatment Guidelines strongly recommend that REGEN-COV™ (casirivimab with imdevimab) be used in non-hospitalized COVID-19 patients ("outpatients") at high risk of clinical progression. The Category 'AIIa' is a 'strong' rating based on results of randomized trials.
- Yahoo Finance Video
Study shows wearables could detect COVID-19 earlier
Tejaswini Mishra, PhD, Research Scientist in the Department of Genetics at Stanford University School of Medicine, joins Yahoo Finance’s Alexis Christoforous to discuss the use of wearables to detect COVID-19.
